News /

CiMaas receives ATMP classification from EMA for NK cell product

CiMaas recently applied for a classification for its’ Advanced Therapeutic Medicinal Product, adoptive NK cell therapy for multiple myeloma. Upon this request, the European Medicines Agency / Committee for Advanced Therapies considers that product NK-Xpand-MM1 falls within the definition of somatic cell therapy medicinal product, as provided in Article 2 of Regulation (EC) No 1394/2007. This classification marks the first step of the regulatory pathway CiMaas has taken to obtain the manufacturing license to produce Natural Killer cells in its’ planned clinical trial for patients with multiple myeloma.
News /

CiMaas receives second tranche of financing

Mercurius Heerlen B.V. and Werker Beleggingsmaatschappij B.V. invested a second round in CiMaas B.V. to realize cancer immunotherapy.
This brings CiMaas again a step closer to fund its’ development of cellular therapies into clinical trials for the patients with multiple myeloma and lung cancer.
News /

CiMaas starts 2017 with successful first investment

MAASTRICHT, Mercurius Beleggingsmaatschappij B.V. and Werker Beleggingsmaatschappij B.V.  invest in CiMaas B.V. to realize cancer immunotherapy. CiMaas is now able to start a clinical trial in late 2017 for lung cancer patients with a cellular vaccine that will stimulate the patients’ own immune system to fight the disease.
News /

CiMaas appoints Dr. Yvo Graus as Chief Operating Officer

Dr Yvo Graus, PhD, MBA, will join the management team of CiMaas. Yvo Graus is an immunologist and has extensive experience in biotechnology. Through his activities at Genmab, Yvo gained great experience in product development from bench to bedside. He worked on the development of products in the laboratory to making them applicable in patients. It goes without saying that we are very happy with this new partnership that will enable us to develop our products further.
News /

CiMaas appoints Drs D.A. van den Noort in Supervisory Board

Drs D.A. van den Noort, MD, and member of the Board of Directors of Bioseutica, has been appointed as first member of the Supervisory Board of CiMaas. Mister van den Noort has tremendous experience in the pharmaceutical industry and is well acquainted with investment instruments in Biotech start-ups. Daan van den Noort: “CiMaas is an exciting company. I see large opportunities for the company and am thrilled to help this young starting company.